Corbus Pharmaceuticals Holdings, Inc. | TalkMarkets

Latest Posts

Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion

Article By: ChinaBio® Today

Saturday, February 18, 2023 12:20 PM EDT

Jiangsu Hengrui Pharma out-licensed US rights for a novel small molecule EZH2 inhibitor in a $706 million agreement with Treeline Biosciences of Connecticut. Hengrui will receive an upfront payment of $11 million.

In this article: CHJTF, CHRS, CRBP, IVBXF, SHJBF, CGEM

Read

March Update: Psychedelic Compounds-Based Drug Stocks Index Went Down -19%

Article By: Lorimer Wilson

Friday, April 1, 2022 8:25 AM EDT

An update on the revisions that have been made to the Pure-Play Psychedelic Compounds-Based Drug Stocks Index with the increase in the minimum market capitalization required to be included in the Index.

In this article: ZYNE, CRBP, RVVTF, DMTTF, CYBN, NUMIF, MNMD, CMPS, FTRP, SEEL, ALID

Read

Psychedelic And Cannabis Drug Stocks Continue Advance

Article By: Lorimer Wilson

Sunday, February 13, 2022 1:22 AM EDT

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

In this article: ATAI, MNMD, CMPS, CRBP, TBPMF, SEEL, GHRS, DMTTF, ALID, AWKNF

Read

Marijuana & Psychedelic Drug Stocks Continue To Decline

Article By: Lorimer Wilson

Sunday, January 16, 2022 3:00 AM EDT

The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 16 of the 100 such companies that trade on North American stock exchanges. 5 of them are marijuana drug stocks and 11 are psychedelic compounds-based drug stocks.

In this article: ZYNE, CRBP, RVVTF, TBPMF, DMTTF, ALID, FTRP, NUMIF

Read